MariaDB SkySQL Adds ‘Power Tier’ for Enterprises That Demand Distinction

REDWOOD CITY, Calif. and HELSINKI – May 13, 2020 – MariaDB® Corporation today announced the immediate availability of MariaDB SkySQL Power, the first database-as-a-service (DBaaS) offering that lets enterprises customize options and configurations to fit their distinct requirements. Built on top of SkySQL’s Foundation, which delivers the complete MariaDB Platform experience in the cloud, Power … Continued

Read More

AIVITA Biomedical Presents Updates from Ongoing Ovarian Cancer and Glioblastoma Clinical Studies at 2020 AACR Virtual Annual Meeting

IRVINE, Calif.–(BUSINESS WIRE)– AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications, announced today that updates from ongoing clinical trials in ovarian cancer and glioblastoma were presented as part of the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I. The presentation from Daniela Bota, MD, Ph.D., of the University … Continued

Read More

AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee

Leader of Series B-2 Financing Round Matthew Katz Joins AIVITA’s Board of Directors IRVINE, Calif., Feb. 25, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a biotechnology company (the “Company”) specializing in innovative stem cell applications, announced today the first closing of its $25 million Series B-2 preferred stock investment round. The first closing of $12.5 million was … Continued

Read More

Brain Cancer Patients Display Appropriate Immune Responses and Decreasing Tumor Biomarkers in AIVITA Biomedical’s Phase 2 Clinical Trial

IRVINE, Calif., Oct. 24, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated data from its ongoing glioblastoma Phase 2 clinical trial investigating AIVITA’s platform immunotherapy targeting tumor-initiating cells. In approximately 80% of treated patients, sequential blood plasma biomarker analyses have identified the induction of a … Continued

Read More

AIVITA Biomedical Announces Publication Comparing Clinical Outcomes in Patients Treated with AIVITA’s Immunotherapy and Other Immunotherapies

New Comparison Indicates Superior Survival IRVINE, Calif., Oct. 17, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotechnology company specializing in innovative stem cell applications, announced the publication of an article titled “Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment“ in … Continued

Read More

Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical’s Phase 2 Clinical Trial

IRVINE, Calif., Aug. 14, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA’s platform immunotherapy targeting tumor-initiating cells. Blood plasma biomarker analyses have identified a robust immune response and a decrease of tumor biomarkers in … Continued

Read More

AIVITA Biomedical Announces New Clinical Data in Ongoing Phase 2 Brain Cancer Trial

IRVINE, Calif., July 8, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today new clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA’s platform immunotherapy targeting cancer stem cells. Blood plasma biomarker analyses have identified predictive markers of efficacy in seven of eight treated … Continued

Read More

ClearFlow Announces Positive Randomized Controlled Trial Results and Inclusion in ERAS Guideline Recommendations

ANAHEIM, Calif.–(BUSINESS WIRE)– ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results of its PleuraFlow® device were presented at the American Association for Thoracic Surgery (AATS) 99th Annual meeting on May 4 in Toronto, Canada. This new data stems from a trial evaluating the use of ClearFlow’s PleuraFlow®Active Clearance Technology® (ACT®) System … Continued

Read More

AIVITA Biomedical Presents New Clinical Data at 2019 ASCO Annual Meeting

IRVINE, Calif., June 3, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that Chief Medical Officer Dr. Robert O. Dillman presented clinical data on melanoma patients treated with patient-specific vaccines on June 1 at the 55th Annual Meeting of ASCO in Chicago, Illinois. The data is being … Continued

Read More

AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy

AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy   Findings suggest a combination with checkpoint inhibitors will enhance response rate beyond 72% survival, and facilitate a new Phase 1B approval   IRVINE, Calif., Feb. 12, 2019 /PRNewswire/ — AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell … Continued

Read More